pharma · Colorectal Cancer · Lymphoma, Extranodal NK-T-Cell
Samsung Bioepis
Samsung Bioepis NL B.V.
Samsung Bioepis clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Yeonsu-gu, Incheon 21987, KR
- Founded
- 2012
- Employees
- 1,589
- Programs
- 24
- Drugs
- 34
- Patents
- 0
Samsung Bioepis projects
4 ClinicalTrials.gov programs sponsored by Samsung Bioepis.
Samsung Bioepis has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Bevacizumab
Samsung Bioepis NL B.V.
Lung Cancer
1 trial -
Intermittent hepatic inflow occlusion (IHIO)
Samsung Bioepis NL B.V.
End Stage Liver Disease
1 trial -
SB11 (Proposed ranibizumab biosimilar)
Samsung Bioepis NL B.V.
Age-Related Macular Degeneration
1 trial -
SB27-3004
Samsung Bioepis NL B.V.
Non-small Cell Lung Cancer
1 trial
Frequently asked questions
How many clinical projects does Samsung Bioepis have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.